Armbrecht U, Svanvik J
Scand J Gastroenterol Suppl. 1986;126:55-9. doi: 10.3109/00365528609091894.
Ten patients with chronic pancreatitis (with abdominal pain and/or diarrhoea) were treated in a double-blind multiple cross-over trial with Pankreon granules 20 g per day or placebo during three periods of one month each. Pain and bowel habits were recorded. Faecal fat and breath hydrogen (H2) excretion were analyzed during the last days of each treatment period. The pain score was initially low in all patients and was not affected by enzymes. The number of daily bowel movements was reduced from 3.16 to 2.32 (n.s.). Faecal fat excretion per 72 hrs was reduced from 357 +/- 158 mmol free fatty acid to 226 +/- 98 mmol (p less than 0.05). With placebo treatment H2 excretion (from 60 and 180 min after a standard breakfast) was significantly increased compared with 19 healthy volunteers (p less than 0.05). It was not significantly reduced by enzymes. In 28 comparisons the H2 output between 60 and 180 min was correlated to faecal fat. In eight patients the oro-coecal transit-time could be determined by the H2 breath test. The transit-time did not differ from that of ten healthy volunteers and remained unchanged by enzymes. Carbohydrate maldigestion occurs parallel to fat maldigestion in chronic pancreatitis, and is not sufficiently reduced by 20 g of pancreatic enzymes.
十名患有慢性胰腺炎(伴有腹痛和/或腹泻)的患者在一项双盲多重交叉试验中接受治疗,在三个为期一个月的时间段内,每天服用20克潘克瑞昂颗粒或安慰剂。记录疼痛情况和排便习惯。在每个治疗期的最后几天分析粪便脂肪和呼气氢气(H2)排泄情况。所有患者的疼痛评分最初都较低,且不受酶的影响。每日排便次数从3.16次减少至2.32次(无统计学意义)。每72小时的粪便脂肪排泄量从357±158毫摩尔游离脂肪酸减少至226±98毫摩尔(p<0.05)。与19名健康志愿者相比,安慰剂治疗时(标准早餐后60分钟和180分钟)的H2排泄量显著增加(p<0.05)。酶治疗后其排泄量无显著降低。在28次比较中,60至180分钟之间的H2排出量与粪便脂肪相关。八名患者的口盲肠转运时间可通过H2呼气试验测定。该转运时间与十名健康志愿者的转运时间无差异,且酶治疗后保持不变。慢性胰腺炎中碳水化合物消化不良与脂肪消化不良同时发生,20克胰酶不能充分降低其程度。